<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660552</url>
  </required_header>
  <id_info>
    <org_study_id>19751975</org_study_id>
    <nct_id>NCT04660552</nct_id>
  </id_info>
  <brief_title>Transcranial Photobiomodulation for Reducing Autism Symptoms in Children</brief_title>
  <acronym>TPBMASD</acronym>
  <official_title>Transcranial Photobiomodulation for Reducing Autism Symptoms in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JelikaLite LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JelikaLite LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is that photobiomodulation reduces symptoms of autism.&#xD;
      Participants will be children between the ages of 2 and 6, who have been diagnosed with&#xD;
      moderate to severe autism. Transcranial photobiomodulation will be administered to the&#xD;
      children in the experimental condition twice a week for 8 weeks. Results will be measured&#xD;
      through parental interviews, standardized CARS (Childhood Autism Rating Scales) and data&#xD;
      collected from EEG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CognilumTM System is a non-invasive device that uses infrared light (IR), delivered&#xD;
      through light emitting diodes (LEDs) built into a head band worn by the patient during&#xD;
      treatment.&#xD;
&#xD;
      The proposed clinical investigation is determined by the FDA to be a nonsignificant risk&#xD;
      (NSR) device study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Randomized, Placebo-controlled, Double Blind, Mixed Design study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>To minimize the bias, Jelikalight hired an independent pediatric psychiatrist, to act as a PI and supervise the study. The PI is blind (and will remain blind until the end of the study data collection and analysis) to the participants' condition. He will supervise data collection and analysis. The PI will supervise parental interviews. The PI will conduct before and after treatment testing of participants with CARS. The PI will supervise analysis for raw data. Experimental and control groups will undergo the same experience apart from having the device turned on or turned off during the sessions. The participants (and their parents) will remain blind to their experimental condition, therefore, ensuring double blindness.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Autism symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Significant change of total score on a Childhood Autism Rating Scales in the experimental condition but not in the control condition (measured by ANOVA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG - 1</measure>
    <time_frame>8 weeks</time_frame>
    <description>Absolute power spectrum alterations will be measured in all oscillatory frequency bands (e.g. Alpha, Beta, Gamma, Delta, Theta, etc.) .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG - 2</measure>
    <time_frame>8 weeks</time_frame>
    <description>The power spectrum across all electrodes for each oscillatory frequency band will be averaged, and the ratio of post- over pre-session rest-EEG for both active and sham conditions will be compared.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>CognilumTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the study participants will be wearing the photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cognilum TM: Light Treatment Condition</intervention_name>
    <description>The children will wear the CognilumTM device for approximately 15 minutes at a time, twice a week, for a period of 8 weeks.</description>
    <arm_group_label>CognilumTM</arm_group_label>
    <arm_group_label>Placebo condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants between 2 years and 6 years of age (inclusive), of all&#xD;
             races.&#xD;
&#xD;
          2. Previously diagnosed with moderate or severe ASD by a licensed professional.&#xD;
&#xD;
          3. Participants may be receiving any behavioral intervention therapy (e.g., ABA, Floor&#xD;
             Time) during the course of the treatment. The final statistical analysis will control&#xD;
             for the participants receiving behavioral therapies in control and experimental&#xD;
             conditions. We expect the majority of the participants in both control and&#xD;
             experimental conditions to be receiving behavioral therapies. There is no known&#xD;
             interactions or complications of tPBM with behavioral therapy.&#xD;
&#xD;
          4. Parents of participants must understand the nature of the study.&#xD;
&#xD;
          5. Parents of participants must sign an IRB- approved informed consent form before&#xD;
             initiation of any study procedures.&#xD;
&#xD;
          6. Parents of participants must have a level of understanding sufficient to communicate&#xD;
             with the investigator and study coordinator, and to cooperate with all tests and&#xD;
             examinations required by the protocol.&#xD;
&#xD;
          7. Participant child experiencing a major psychiatric disorder will be allowed to&#xD;
             participate in the study provided they do not meet any exclusionary criteria.&#xD;
&#xD;
          8. The participant child is willing to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant child is experiencing severe self-injurious behavior or severe aggressive&#xD;
             behavior to self or others (within past 7 days).&#xD;
&#xD;
          2. Participant has been diagnosed with another psychiatric or neurological disorder (e.g.&#xD;
             epilepsy) or have exhibited symptoms of major psychiatric disorders within the last 30&#xD;
             days.&#xD;
&#xD;
          3. Participant has an unstable medical condition (that requires clinical attention).&#xD;
&#xD;
          4. Participant has a significant skin condition at the procedure sites (i.e., hemangioma,&#xD;
             scleroderma, psoriasis, rash, open wound or tattoo).&#xD;
&#xD;
          5. Participant has an implant of any kind in the head (e.g. stent, clipped aneurysm,&#xD;
             embolised AVM, implantable shunt - Hakim valve).&#xD;
&#xD;
          6. Participant has receiving medication on a regular basis for Autism or any other&#xD;
             medical condition.&#xD;
&#xD;
          7. Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study&#xD;
             enrollment (in US: Visudine (verteporfin) - for age related macular degeneration;&#xD;
             Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for&#xD;
             esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid&#xD;
             HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin&#xD;
             cancer).&#xD;
&#xD;
          8. Current treatment with a psychotropic medication.&#xD;
&#xD;
          9. Investigator and his/her immediate family, defined as the investigator's child or&#xD;
             grandchild.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuli Fradkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RDT Group NJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katya Sverdlov, Esq.</last_name>
    <phone>19175668151</phone>
    <email>katya@jelikalite.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugenia Steingold, PhD</last_name>
    <phone>8576360893</phone>
    <email>dr.eugenia.steingold@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Steingold Psychology PC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Sverdlov, Esq.</last_name>
      <phone>917-566-8151</phone>
      <email>katya@jelikalite.com</email>
    </contact>
    <contact_backup>
      <last_name>Eugenia Steingold, PhD</last_name>
      <phone>8576360893</phone>
      <email>dr.eugenia.steingold@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yuli Fradkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Steingold Psychology PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Sverdlov, Esq.</last_name>
      <phone>917-566-8151</phone>
      <email>katya@jelikalite.com</email>
    </contact>
    <contact_backup>
      <last_name>Eugenia Steingold, PhD</last_name>
      <phone>8576360893</phone>
      <email>dr.eugenia.steingold@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bosl WJ, Tager-Flusberg H, Nelson CA. EEG Analytics for Early Detection of Autism Spectrum Disorder: A data-driven approach. Sci Rep. 2018 May 1;8(1):6828. doi: 10.1038/s41598-018-24318-x.</citation>
    <PMID>29717196</PMID>
  </reference>
  <reference>
    <citation>Hamblin MR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clin. 2016 Oct 1;6:113-124. eCollection 2016 Dec. Review.</citation>
    <PMID>27752476</PMID>
  </reference>
  <reference>
    <citation>Henderson TA, Morries LD. Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain? Neuropsychiatr Dis Treat. 2015 Aug 21;11:2191-208. doi: 10.2147/NDT.S78182. eCollection 2015. Review.</citation>
    <PMID>26346298</PMID>
  </reference>
  <reference>
    <citation>Khuman J, Zhang J, Park J, Carroll JD, Donahue C, Whalen MJ. Low-level laser light therapy improves cognitive deficits and inhibits microglial activation after controlled cortical impact in mice. J Neurotrauma. 2012 Jan 20;29(2):408-17. doi: 10.1089/neu.2010.1745. Epub 2011 Sep 21.</citation>
    <PMID>21851183</PMID>
  </reference>
  <reference>
    <citation>Leisman G, Machado C, Machado Y, Chinchilla-Acosta M. Effects of Low-Level Laser Therapy in Autism Spectrum Disorder. Adv Exp Med Biol. 2018;1116:111-130. doi: 10.1007/5584_2018_234.</citation>
    <PMID>29956199</PMID>
  </reference>
  <reference>
    <citation>Weissman JR, Kelley RI, Bauman ML, Cohen BH, Murray KF, Mitchell RL, Kern RL, Natowicz MR. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One. 2008;3(11):e3815. doi: 10.1371/journal.pone.0003815. Epub 2008 Nov 26.</citation>
    <PMID>19043581</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data (IPD) will be available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

